摘要
目的分析艾司氯胺酮联合舒芬太尼在全髋关节置换术后镇痛中的临床效果。方法选取2020年3月至2021年3月于浙江省绍兴第二医院接受全髋关节置换术的患者86例,采用随机数字表法分为对照组(n=43)与观察组(n=43)。对照组予舒芬太尼术后镇痛,观察组予艾司氯胺酮联合舒芬太尼术后镇痛,观察并记录两组患者术后各时间点视觉模拟评分(visual analogue scale,VAS)、镇静评分、不良反应情况及术后髋关节功能恢复情况。结果①观察组患者术后各时间点VAS均低于对照组(P<0.05);②观察组患者术后各时间点镇静评分明显低于对照组(P<0.05);③观察组患者术后的不良反应发生率为11.63%,明显低于对照组患者术后的不良反应发生率为27.91%,差异有统计学意义(P<0.05);④观察组患者术后髋关节功能恢复总优良率为93.02%,明显高于对照组的74.42%,差异有统计学意义(P<0.05)。结论艾司氯胺酮联合舒芬太尼静脉自控镇痛能提高全髋关节置换术后镇痛及镇静效果,减少不良反应发生,有利于术后髋关节功能恢复。
Objective To investigate the clinical effect of S-ketamine combined with sufentanil in postoperative analgesia after total hip arthroplasty.Methods A total of 86 patients with total hip arthroplasty from March 2020 to March 2021 were selected and randomly divided into control group(n=43)and observation group(n=43).The control group was given sufentanil,and the observation group was given S-ketamine combined with sufentanil.The visual analysis scale(VAS)score,sedation score,adverse reactions and hip joint function recovery of the two groups at each time point after surgery was observed and recorded.Results①The VAS score of the observation group at each time point was lower than that of the control group(P<0.05);②The sedation score of the observation group was significantly different from that of the control group at each time point after operation(P<0.05);③The incidence of adverse reactions was 11.63%in the observation group,was lower the control group was 27.91%,with significant difference(P<0.05);④The total excellent and good rate of hip joint function recovery in the observation group was 93.02%,which was higher than 74.42%in the control group,with significant difference(P<0.05).Conclusion Patient controlled intravenous analgesia with S-ketamine and sufentanil can improve the effect of analgesia and sedation after total hip arthroplasty,reduce the incidence of adverse reactions,and contribute to the recovery of hip joint function after total hip arthroplasty.
作者
蔡璐
陈公锦
王昌盛
CAI Lu;CHEN Gongjin;WANG Changsheng(Department of Anesthesiology,General Hospital of Medical Community,Shaoxing Second Hospital,Zhejiang,Shaoxing 312000,China)
出处
《中国现代医生》
2022年第36期71-74,共4页
China Modern Doctor
基金
浙江省自然科学基金(LQ22H090015)。
